Patents · October 19, 2026
How Can Biotech Startups Protect Their Intellectual Property Before Raising Funding in Irvine, CA?
A strong biotech IP strategy before raising funding means filing a provisional patent application before any public disclosure, securing signed invention assignments from every founder and employee, and documenting trade secrets and licenses so investors can verify clean ownership. U.S. law gives a one-year grace period, but Europe generally does not. Learn about patent protection and our Irvine patent law services.
What Is a Biotech IP Strategy Before Raising Funding?
A biotech IP strategy before raising funding is a plan to secure ownership and filing dates for your core science before you share it with investors, partners, or the public. It usually combines early patent filings, signed invention assignments, confidentiality agreements, and a record of what the company keeps as trade secrets. Investors in life sciences often treat intellectual property as the main asset, because a startup may have no revenue for years while a product moves through research and clinical work. If ownership is unclear or a key disclosure happened before filing, a valuation can drop or a deal can stall. Building the strategy early also helps founders decide which data to publish, which experiments to run before filing, and how to describe the technology in a pitch deck without giving away unprotected details.
Should You File a Provisional Patent Before Pitching Investors?
Yes, in most cases you should file a provisional patent application before pitching investors or presenting at a conference. A provisional application gives you a U.S. filing date and patent pending status for 12 months under 35 U.S.C. 119(e), and it is not examined. The USPTO filing fee is currently $325 undiscounted, $130 for a small entity, or $65 for a micro entity. The provisional only protects what it actually describes, so a short summary or slide deck rarely supports the claims you will need later. Biotech provisionals should include sequences, data, methods, and alternative embodiments where possible. Before the 12 months expire, you must file a non-provisional or PCT application to keep the priority date. Our guide to provisional vs. non-provisional patents explains the tradeoffs in detail.
How Does First-Inventor-to-File Affect Biotech Startups?
Under the America Invents Act, the United States uses a first-inventor-to-file system for applications with an effective filing date on or after March 16, 2013, so filing early matters. If two parties independently develop the same invention, the earlier filer usually has the advantage. U.S. law under 35 U.S.C. 102(b)(1) gives inventors a one-year grace period after their own disclosure, but most other major markets do not. The European Patent Office applies a strict absolute novelty standard with no general grace period, so a publication, poster, or unprotected investor pitch can destroy European rights even when U.S. rights survive. Many biotech products need global protection to attract partners, so the safer practice is to file before any disclosure. Patent applications also publish about 18 months after the earliest priority date, which affects when competitors see your work.
Who Owns Biotech Inventions Created by Founders and Employees in California?
In California, the company owns employee and founder inventions only if those people sign valid written assignments, so every contributor should sign an invention assignment agreement early. California Labor Code section 2870 limits these agreements: an employer cannot require assignment of an invention developed entirely on the employee’s own time without company equipment, supplies, facilities, or trade secrets, unless it relates to the employer’s business or results from work for the employer. Section 2872 requires employers to give written notice of this limit. Founders coming from universities face another layer. The University of California Patent Policy requires employees to disclose inventions and assign rights to the university, so UC Irvine spinouts usually need a license. In Stanford v. Roche (2011), the Supreme Court held that the Bayh-Dole Act does not automatically give universities title, which shows how assignment wording matters.
When Should Biotech Startups Use NDAs and Trade Secrets?
Biotech startups should use nondisclosure agreements whenever they share unfiled science with vendors, contract research organizations, potential partners, or advisors, and should treat manufacturing know-how as trade secrets. Many venture investors decline to sign NDAs, which is another reason to file before pitching. Trade secret protection can last indefinitely, but only if the company takes reasonable measures to keep the information secret. The federal Defend Trade Secrets Act of 2016, codified at 18 U.S.C. 1836, and the California Uniform Trade Secrets Act, Civil Code section 3426 and following, both require those reasonable efforts. Practical steps include access controls, marked confidential documents, employee training, and exit interviews. Processes that cannot be reverse engineered from a final product are good trade secret candidates. Our article on patent vs. trade secret protection covers this choice further.
What Will Investors Check During Biotech IP Due Diligence?
Investors check whether the company truly owns or controls the IP it is pitching, whether that IP can block competitors, and whether the product can launch without infringing others. Due diligence teams often review filed applications, assignment records, license terms, and any public disclosures before filing. Recording assignments with the USPTO matters, because 35 U.S.C. 261 can make an unrecorded assignment void against a later purchaser who records first. Many investors also ask for a freedom-to-operate analysis, which looks at third-party patents that could cover the product, separate from your own patentability. Preparing this package before a seed or Series A round can shorten the process. Diligence teams commonly request the following items.
- Signed invention assignments from all founders, employees, and consultants
- Recorded USPTO assignments for every patent application
- University or corporate license agreements and their milestone terms
- A list of publications, posters, and pitches with dates compared to filing dates
- Freedom-to-operate analysis for the lead product
- Written trade secret policies and confidentiality agreements
Where Can You Get Help With Biotech IP Strategy in Irvine, CA?
You can get help with biotech IP strategy from mjIP, an intellectual property law firm in Irvine, CA, that has served biotech, pharmaceutical, and supplement companies and startups since 2010. Founding attorney Mandana Jafarinejad, Esq., is a USPTO-registered patent attorney with a biology degree and in-house experience at a Fortune 500 pharmaceutical company in Orange County, which helps when translating lab work into patent filings before a funding round. The firm serves Irvine, Orange County, San Diego, and the Bay Area. Explore our Irvine patent law services, then contact us to schedule a free consultation, or call (949) 833-7125. This article is general information, not legal advice, and reading it does not create an attorney-client relationship.
Common Questions
Frequently Asked Questions About Biotech IP Strategy in Irvine, CA
You can, but it carries risk. The United States gives inventors a one-year grace period after their own disclosure, while Europe and many other markets generally do not. Many venture investors also refuse to sign NDAs. Filing a detailed provisional application before pitching is the safer path for most biotech startups that may want international protection.
A provisional application lasts 12 months from its filing date and cannot be extended for most purposes. During that time you can use the term patent pending. To keep the priority date, you must file a non-provisional U.S. application or a PCT international application claiming the provisional before the 12 months end.
It depends on your employment agreement and when and how you developed the invention. California Labor Code section 2870 protects inventions developed entirely on your own time without employer resources or trade secrets, unless they relate to the employer’s business or result from your work there. Review your signed agreements before forming a company around the invention.
Usually yes. The University of California Patent Policy requires employees and others using UC facilities or funds to disclose inventions and assign rights to the university. A startup typically needs a license agreement from the campus technology transfer office before investors will treat the technology as company property. License terms such as milestones, royalties, and field limits also affect valuation.
A freedom-to-operate analysis reviews existing patents owned by others to judge whether making, using, or selling your product could infringe them. It is different from a patentability search, which asks whether your invention is new. Investors in biotech often request it before a significant round, especially for a lead drug candidate or platform.
Trade secrets can protect manufacturing methods, cell line handling, and other know-how that competitors cannot discover from the product. They do not stop independent discovery or reverse engineering, and they require reasonable secrecy measures under federal and California law. Most biotech companies combine patents for core inventions with trade secrets for process details.